Illumina TruPath Genome Now Available as a Pilot Service at NGI
The National Genomics Infrastructure (NGI) is now offering Illumina TruPath Genome as a pilot sequencing service, open to researchers interested in exploring the capabilities of this new whole-genome sequencing technology.
What is TruPath Genome?
Illumina TruPath Genome transforms whole-genome sequencing (WGS) by combining the accuracy and accessibility of short-read sequencing with long-range insights traditionally limited to long-read platforms.
The technology is based on a proximity mapped read technology enabled by on-flowcell library preparation incorporating proximity information from clusters in nearby nanowells to generate long-range genomic information. Sequencing produces standard short reads (2×150 bp), with the proximity information maintaining the link back to the original large DNA template.
- Sequencing read length: 2×150 bp (standard short reads, same as regular NovaSeq X WGS)
- Effective long-range information: Median fragment length is 10-30 kb with up to >100 kb templates in the top percentile (based on preliminary data from NGI)
What Can TruPath Genome Detect?
Analysis is performed using the DRAGEN Germline pipeline on our on-premises DRAGEN server, currently supporting diploid genomes (as of v4.6, non-human genomes are experimental). The pipeline includes a comprehensive set of variant types:
- Small variants (SNVs and indels) with high-accuracy, phased calls
- Structural variants (SVs) with haplotype-resolved genotyping
- Copy number variants (CNVs)
- Short tandem repeats (STRs), including estimation of large repeat expansions such as Fragile X
- Multi-Region Joint Detection (MRJD) for resolution of clinically relevant paralogous gene families
Please note that some analyses, including STR genotyping and Multi-Region Joint Detection (MRJD), are currently only supported for the human hg38 reference genome.
Proximity information enables high-confidence mapping of highly homologous, repetitive, and segmentally duplicated regions, with demonstrated recovery of coverage in medically relevant genes such as STRC and PMS2, which contain more than 99% identical pseudogenes that confound standard WGS.
Sample Requirements
TruPath Genome requires high molecular weight (HMW) DNA for optimal performance. Key requirements include:
- Input amount: 350 ng recommended (minimum 175 ng, though reduced coverage may result). Note: this amount is required after NGI’s QC step, which uses 4–5 µL of the submitted sample.
- Concentration: 2-100 ng/µL
- Quality assessment: Genomic Quality Number GQN(10kb) ≥ 7.0 and GQN(60kb) ≥ 4.0 recommended, assessed by Agilent gDNA ScreenTape or Femto Pulse
- DNA handling: Please avoid vortexing; use wide-bore pipette tips and minimize freeze-thaw cycles
NGI’s Pilot Offering
NGI is currently accepting pilot projects for TruPath Genome sequencing. We accept full flow cell runs only, which correspond to:
- 2 samples — NovaSeq X C2 flow cell (total price ca 20 000 SEK / 10 000 SEK per sample)
- 8 samples — NovaSeq X C8 flow cell (total price ca 40 000 SEK / 5 000 SEK per sample)
Each lane will produce roughly 240 Gbp of data, or around 60X human genome coverage.
Please note that prices are approximate and subject to change.
This service is particularly well-suited for researchers who:
- Require haplotype-resolved or phased whole-genome data from a single sample
- Work with genomic regions that are difficult to resolve with standard short-read sequencing, such as segmental duplications, pseudogenes, or difficult-to-map regions
- Are investigating structural variants, complex rearrangements, or tandem repeat disorders
- Seek a simpler, faster sample-to-sequencer workflow without sacrificing genomic comprehensiveness
A technical note describing our implementation, QC metrics, and example data is currently in preparation and will be published shortly. This note will provide researchers with detailed benchmarking data to help assess whether TruPath Genome is the right fit for their projects.
Get in Touch
If you are interested in participating in the TruPath Genome pilot or would like to discuss whether this technology is a good fit for your research, we encourage you to contact us to schedule a consultation with our team. We are happy to discuss your project, sample requirements, and expected data outputs before you commit.
Illumina resources
- TruPath Genome performance with samples of varying type and quality
- TruPath™ to long-range, accurate haplotype phasing
- Informatics advances reveal the TruPath™ Genome towards comprehensive genomic insights
Last Updated: 19th November 2026